

## Technology Appraisal Committee Meeting (Committee [A])

**Minutes:** [Confirmed]

**Date and Time:** Thursday 8 June 2017, 10am

**Venue:** NICE London Office  
Prince of Wales Suite 10 Spring Gardens SW1A 2BU

<b>Present:</b>	1. Chair Jane Adam	Present for all notes
	2. Professor Iain Squire	Present for all notes
	3. Dr Graham Ash	Present for all notes
	4. Dr Jeremy Braybrooke	Present for all notes
	5. Mr John Cairns	Present for all notes
	6. Dr Justin Daniels	Present for all notes
	7. Dr Andrew England	Present for all notes
	8. Mr David Evans	Present for notes 17 to 25
	9. Dr Rita Faria	Present for all notes
	10. Mr Adrian Griffin	Present for all notes
	11. Dr Mohit Misra	Present for all notes
	12. Dr Mohit Sharma	Present for all notes
	13. Dr Ian Bernstein	Present for all notes
	14. Mrs Sarah Parry	Present for all notes
	15. Dr Paul Robinson	Present for all notes
	16. Dr Brian Shine	Present for all notes

### In attendance:

Meindert Boysen	Programme Director, National Institute for Health and Care Excellence	Present for all notes
Janet Robertson	Associate Director, National Institute for Health and Care Excellence	Present for all notes
<b>Jeremy Powell</b>	Project Manager, National Institute for Health and Care Excellence	Present for all notes

Marcia Miller	Technology Appraisal Administrator, National Institute for Health and Care Excellence	Present for all notes
Anwar Jilani	Technical Analyst, National Institute for Health and Care Excellence	Present for notes xx to xx
Joanna Richardson	Technical Adviser, National Institute for Health and Clinical Excellence	Present for notes xx to xx
Sana Khan	Technical Analyst, National Institute for Health and Care Excellence	Present for notes 8 to 16
Hamish Lungaria	Technical Analyst, National Institute for Health and Clinical Excellence	Present for notes xx to xx
Zoe Charles	Technical Adviser, National Institute for Health and Clinical Excellence	Present for notes xx to xx
Keith Cooper	Southampton Technology Assessment, University of Southampton	Present for notes xx to xx
Jo Lord	Southampton Technology Assessment University of Southampton	Present for notes xx to xx
Angela Stainthorpe	Liverpool Reviews and Implementation Group, <i>LRiG</i>	Present for notes 17 to 26
Rumona Dickson	Liverpool Reviews and Implementation Group, <i>LRiG</i>	Present for notes to 17 To 26
Rob Riemsma	Kleijnen Systematic Reviews	Present for notes

Sabine Grimm	Kleijnen Systematic Reviews	Present for notes
Dr Nick Turner	Clinical expert nominated by RCP	Present for notes 17 to 25
Miss Melanie Sturtevant	Patient expert nominated by Breast Cancer Now.	Present for notes 17 to 25

## Notes

### Welcome

1. The Chair welcomed all members of the Committee and other attendees present to the meeting. The Chair reviewed the agenda and timescales for the meeting, which included the appraisals of Reslizumab for treating eosinophilic asthma inadequately controlled on inhaled corticosteroids [ID872]
2. The Chair informed the Committee of the non-public observers at this meeting: Joshua South, Chloe Kastoryano Jane Lynn,
3. Apologies were received from Dr Rachel Hobson, Dr Anne McCune, Professor John McMurray, Professor Oliva Wu, Dr Nerys Woolacott, Ms Ellen Rule, Mr Stephen Sharp and Ms Pamela Rees

### Notes from the last meeting

4. The minutes from the last meeting were agreed.

### Appraisal of Reslizumab for treating eosinophilic asthma inadequately controlled on inhaled corticosteroids

#### Part 1 – Open session

5. The Chair welcomed the invited experts: Keith Cooper and Jo Lord to the meeting and they introduced themselves to the Committee.
6. The Chair welcomed company representatives from Teva to the meeting.
7. The Chair asked all Committee members to declare any relevant interests
  - 7.1. Dr Jane Adam, Dr Graham Ash, Dr Jeremy Braybooke, Mr John Cairns, Dr Justin Daniels, Mr Andrew England, Mr David Evans, Dr Rita Faria, Mr Adrian Griffin, Dr Mohit Misra, Dr Mohit Sharma, Dr Ian Bernstein, Mrs Sarah Parry, Dr Paul Robinson and Dr Brian Shine declared that they knew of no personal specific financial interest, personal non-specific

financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of Reslizumab for treating eosinophilic asthma inadequately controlled on inhaled corticosteroids

- 7.2. Professor Iain Squire declared a personal non-specific financial interest as he has received honoraria from Novartis and support for research in cardiovascular disease.

9.2.1 It was agreed that this declaration would not prevent Professor Iain Squire from participating in this section of the meeting.

8. The Chair asked all NICE Staff to declare any relevant interests.

- 8.1. All declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of Reslizumab for treating eosinophilic asthma inadequately controlled on inhaled corticosteroids.

9. The Chair asked all other invited guests (ERG and invited experts, not including observers) to declare their relevant interests.

- 9.1. All declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of Reslizumab for treating eosinophilic asthma inadequately controlled on inhaled corticosteroids

10. The Chair introduced the key themes arising from the consultation responses to the Appraisal Consultation Document (ACD) received from consultees, commentators and through the NICE website.

11. The Chair asked the company representatives whether they wished to comment on any matters of factual accuracy.

12. The Chair explained that “representatives of the press and other members of the public be excluded from the remainder of this meeting having regard to the confidential nature of the business to be transacted, publicity on which would be prejudicial to the public interest” (Section 1(2) Public Bodies (Admission to Meetings) Act 1960)” and all public attendees left the meeting.

13. The Chair then thanked the experts and company representatives for their attendance, participation and contribution to the appraisal and they left the meeting.

## **Part 2 – Closed session**

14. Discussion on confidential information continued. This information was supplied by the company.

15. The Committee continued to discuss the clinical and cost effectiveness of **Reslizumab for treating eosinophilic asthma inadequately controlled on inhaled corticosteroids**
16. The Committee instructed the technical team to prepare the Final Appraisal Determination (FAD)] in line with their decisions.

**Appraisal of Palbociclib in combination with an aromatase inhibitor for previously untreated metastatic, hormone receptor-positive, HER2-negative breast cancer [ID915]**

**Part 1 – Open session**

17. The Chair welcomed the invited experts: Dr Nicholas Turner, Melanie Sturtevant to the meeting and they introduced themselves to the Committee.
18. The Chair welcomed company representatives from Pfizer to the meeting.
19. The Chair asked all Committee members to declare any relevant interests
  - 19.1. Dr Jane Adam, Dr Graham Ash, Dr Jeremy Braybrooke, Mr John Cairns, Dr Justin Daniels, Mr Andrew England, Mr David Evans, Dr Rita Faria, Mr Adrian Griffin, Dr Mohit Misra, Dr Mohit Sharma, Dr Ian Bernstein, Mrs Sarah Parry, Dr Paul Robinson and Dr Brian Shine all declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of Palbociclib in combination with an aromatase inhibitor for previously untreated metastatic, hormone receptor-positive, HER2-negative breast cancer.
  - 19.2. Professor Iain Squire declared a personal non-specific financial interest as he has received honoraria from Novartis and support for research in cardiovascular disease.
    - 9.2.1 It was agreed that this declaration would not prevent Professor Iain Squire from participating in this section of the meeting
  - 19.3. Mr David Evans declared a personal specific financial interest as he holds shares in the comparator company AstraZeneca.
    - 9.3.1 It was agreed that this declaration would prevent Mr David Evans from participating in this section of the meeting and he observed Part 1 of the meeting only.
20. The Chair asked all NICE Staff to declare any relevant interests.
  - 20.1. All declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of Palbociclib in combination with an aromatase inhibitor for previously untreated metastatic, hormone receptor-positive, HER2-negative breast cancer.

The Chair asked all other invited guests (assessment group/ERG and invited experts, not including observers) to declare their relevant interests.

21. Angela Stainthorpe, Rumona Dickson all declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of Palbociclib in combination with an aromatase inhibitor for previously untreated metastatic, hormone receptor-positive, HER2-negative breast cancer.
  - 21.1. Dr Nicholas Turner declared a personal specific pecuniary interest as he has sat on advisory boards and received honoraria and research funding from Pfizer
    - 21.1.1. It was agreed that this declaration would not prevent Dr Nicholas Turner from participating in the meeting.
  - 21.2. Melanie Sturtevant declared a personal specific pecuniary interest as her employer Breast Cancer Now receives funding from Pfizer for its catalyst research programme this is separate/independent to their policy and campaign work.
    - 21.2.1. It was agreed that this declaration would not prevent Dr Nicholas Turner from participating in the meeting.
22. The Chair introduced the key themes arising from the consultation responses to the Appraisal Consultation Document (ACD) received from consultees, commentators and through the NICE website.
23. The Chair asked the company representatives whether they wished to comment on any matters of factual accuracy.
24. The Chair explained that “representatives of the press and other members of the public be excluded from the remainder of this meeting having regard to the confidential nature of the business to be transacted, publicity on which would be prejudicial to the public interest” (Section 1(2) Public Bodies (Admission to Meetings) Act 1960)” and all public attendees left the meeting.
25. The Chair then thanked the experts and company representatives for their attendance, participation and contribution to the appraisal and they left the meeting.

## **Part 2 – Closed session**

26. Discussion on confidential information continued. This information was supplied by the company.
27. The Committee continued to discuss the clinical and cost effectiveness of Palbociclib in combination with an aromatase inhibitor for previously untreated metastatic, hormone receptor-positive, HER2-negative breast cancer.
28. The Committee instructed the technical team to prepare the Final Appraisal Determination (FAD) in line with their decisions.

## Appraisal of Naltrexone-bupropion (prolonged-release) for managing overweight and obesity (ID757)

### Part 1 – Open session

- 29.. The Chair welcomed the invited experts: Dr Barbara McGowan, Rob Riemsma and Sabine Grimme to the meeting and they introduced themselves to the Committee.
30. The Chair welcomed company representatives from Orexigen Therapeutics to the meeting.
31. The Chair asked all Committee members to declare any relevant interests
- 19.1. Dr Jane Adam, Dr Graham Ash, Dr Jeremy Braybooke, Mr John Cairns, Dr Justin Daniels, Mr Andrew England, Mr David Evans, Dr Rita Faria, Mr Adrian Griffin, Dr Mohit Misra, Dr Mohit Sharma, Dr Ian Bernstein, Mrs Sarah Parry, Dr Paul Robinson and Dr Brian Shine all declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of Naltrexone-bupropion (prolonged-release) for managing overweight and obesity.
- 19.2. Professor Iain Squire declared a personal non-specific financial interest as he has received honorarium from Novartis and support for research in cardiovascular.
- 19.2.1 It was agreed that this declaration would not prevent Professor Iain Squire from participating in this section of the meeting
- 19.3. Mr David Evans declared a personal specific financial interest as he holds shares in the comparator company AstraZeneca.
- 19.3.1 It was agreed that this declaration would prevent Mr David Evans from participating in this section of the meeting and remained absent from the meeting.
20. The Chair asked all NICE Staff to declare any relevant interests.
- 20.1. All declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of Naltrexone-bupropion (prolonged-release) for managing overweight and obesity (ID757)
21. The Chair asked all other invited guests the ERG and invited experts, not including observers) to declare their relevant interests.

- 21.1. Rob Riemsma and Sabine Grimm declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of Naltrexone-bupropion (prolonged-release) for managing overweight and obesity.
- Dr Barbara McGowan declared a personal specific pecuniary interest as she has participated in pharmaceuticals advisory meetings including for Orexigan in the past Clinical Lead and Principal Investigator for commercial and clinical trials in obesity.
- 28.1.1. It was agreed that this declaration would not prevent Dr Barbara McGowan from participating in the meeting.
22. The Chair introduced the key themes arising from the consultation responses to the Appraisal Consultation Document (ACD) received from consultees, commentators and through the NICE website.
23. The Chair asked the company representatives whether they wished to comment on any matters of factual accuracy.
24. The Chair explained that “representatives of the press and other members of the public be excluded from the remainder of this meeting having regard to the confidential nature of the business to be transacted, publicity on which would be prejudicial to the public interest” (Section 1(2) Public Bodies (Admission to Meetings) Act 1960)” and all public attendees left the meeting.
25. The Chair then thanked the experts and company representatives for their attendance, participation and contribution to the appraisal and they left the meeting.

## Part 2 – Closed session

26. Discussion on confidential information continued. This information was supplied by the company.
27. The Committee continued to discuss the clinical and cost effectiveness of
28. The Committee instructed the technical team to prepare the [Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD)] in line with their decisions.

## **Date, time and venue of the next meeting**

29. Tuesday 8 August 2017, 10am at NICE London Office, Prince of Wales Suite 10 Spring Gardens SW1A 2BU